Scientific clarity
for high-stakes
investment decisions
Independent scientific insight into sequencing, spatial and genomics platforms — curated biotech consulting from internationally recognized key opinion leaders.
genomic
expertise
for scientific
diligence
About us
Codex Insights is a independent biotechnology diligence platform specializing in genomics, sequencing and spatial technologies.
Founded by Prof. Holger Heyn, a globally recognized leader in single-cell and spatial genomics, Codex Insights connects life-science investors with internationally recognized key opinion leaders for precise technical assessment.
We focus on depth and relevance — providing curated biotech consulting that supports critical investment decisions with independent scientific clarity.
Our Genomics Consultants
Clarify
expert fit before you engage
Not sure which consultant best aligns with your specific investment topic?
Submit up to three concise screening questions. Your request can be shared with selected consultants of your choice.
You will receive short, structured responses to help determine fit before scheduling a full consultation.
The screening process is provided as a courtesy and does not require a booking.
Here is how it works:
Quality
Choose from internationally recognized key opinion leaders in sequencing, spatial and genomics.
Selected for deep scientific authority and relevance to your specific investment question.
Speed
Engage directly with the right expert without prolonged coordination or intermediary layers.
Keeping your diligence process moving.
Simplicity
Standardized agreements and streamlined coordination ensure that expert insight integrates efficiently into your deal process.
Recent developments across genomics signal a shift in the field’s trajectory. As sequencing, spatial, and multiomic technologies continue to evolve, the focus is moving toward scalability, integration, and real-world application. Codex Insights highlights the trends shaping how genomics may translate into impact in 2026.
More insights in our bi-weekly newsletter.